RAP 0.00% 20.5¢ resapp health limited

rap chart, page-72

  1. 891 Posts.
    lightbulb Created with Sketch. 237
    I agree with most of what you have said here.
    It it true that both the Respiratory and Sleep Apnoea markets are very large indeed, and growing
    but the class action ideas seem a bit out there.

    I would say that I think having such a good start with sleep apnoea will be a great potential risk reducer. Success in the sleep market alone could be worth many times the current market cap if successful.

    And on top of that there are still other application that they are working on but cant yet talk about which could yield something in the future.
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.